Can minocycline prevent the onset of Alzheimer's disease?

Annals of Neurology

Volumn 69, Issue 4, 2011, Pages 739-

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; BIOLOGICAL MARKER; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA SECRETASE; MINOCYCLINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11;

ALZHEIMER DISEASE; BRAIN; CELL DEATH; COMPETITIVE INHIBITION; HUMAN; LETTER; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION;

ALZHEIMER DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; LIPOXYGENASE INHIBITORS; MICE; MICE, TRANSGENIC; MICROGLIA; MINOCYCLINE; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS;

EID: 79955424909     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22378     Document Type: Letter

References (5)

1. Chu J, Pratico D,. 5-Lipoxygenase as an endogenous modulator of amyloid-β formation in vivo. Ann Neurol 2011; 69: 34-46.
2. Diruzi O, Zhuo J, Chinnici C, et al. 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease. FASEB J 2008; 22: 1169-1178. (Pubitemid 351519971)
3. Song Y, Wei EQ, Zhang WP, et al. Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res 2006; 1085: 57-67. (Pubitemid 43728193)
4. Cuello AC, Ferretti M, Leon WC, et al. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 2010; 7: 96-98.
5. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009; 72: 56-62.